{"chunk_id": "medquad__chunk_6187", "source": "medquad", "text": "s:            -  Trastuzumab, lapatinib, pertuzumab, or mTOR inhibitors.     -  Antibody-drug conjugate therapy with ado-trastuzumab emtansine.     - Cyclin-dependent kinase inhibitor therapy (palbociclib) combined with letrozole.           In women with metastatic breast cancer that is HER2/neu positive, treatment may include:             - Targeted therapy such as trastuzumab, pertuzumab, ado-trastuzumab emtansine, or lapatinib.                Chemotherapy     In women with metastatic breast c"}